Video

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Author(s):

Andreas du Bois, MD
Conference|ASCO Annual Meeting

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

To read more about this study >>>

<<<

View more from the 2013 ASCO Annual Meeting

Related Videos
Angeles A. Secord, MD, MHSc
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Kimberly Cannavale, MPH
Related Content
Roopal Thakkar, MD
September 20th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

David A. Braun, MD, PhD, of Yale School of Medicine
September 19th 2024

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Alexander Spira, MD, PhD, FACP
September 18th 2024

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

Anna Dańska-Bidzińska, MD, a gynecologist from Warsaw Medical University in Warsaw, Poland
September 18th 2024

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer